Indian J Crit Care Med
August 2024
Khilnani GC, Tiwari P, Mittal S, Kulkarni AP, Chaudhry D, Zirpe KG, Guidelines for Antibiotics Prescription in Critically Ill Patients. Indian J Crit Care Med 2024;28(S2):S104-S216.
View Article and Find Full Text PDFThough echinocandins are the first line of therapy for C. auris candidemia, there is little clinical data to guide the choice of therapy within this class. This was the first study to compare the three echinocandins in terms of efficacy and outcomes for C.
View Article and Find Full Text PDFIntroduction: Candida auris is emerging as an important cause of candidemia and deep seated candidal infection. We compared the susceptibility results of bloodstream Candida auris isolates by Vitek 2 with Sensititre YeastOne (SYO) method.
Methods: Forty-seven C.
Indian J Crit Care Med
February 2024
Objectives: Fecal microbiota transplantation (FMT) is an emerging option for recurrent or refractory -associated diarrhea (CDAD). We describe a single-center experience of FMT in hematopoietic stem cell transplant (HSCT) recipients with CDAD in India.
Methods: A prospective observational study of HSCT recipients with CDAD who received FMT in our center.
Indian J Crit Care Med
September 2023
Introduction: In the Indian setting, antimicrobial resistance in is a considerable problem, especially in intensive care units (ICUs). Due to the limited data, clinicians are left with very few choices except polymyxins for treating serious infections caused by . There is sparse data regarding the local mechanisms of resistance.
View Article and Find Full Text PDFIntroduction: Gram-negative sepsis remains one of the most difficult to treat infections in intensive care units (ICUs). Carbapenems are often considered to be robust and reliable options for treating infections due to Gram-negative bacteria. The dominance of carbapenem-resistant enterobacteriaceae (CRE) has emerged as one of the greatest challenges faced by the medical community today.
View Article and Find Full Text PDF: Prayag PS. Author Reply: Therapeutic Drug Monitoring of Isavuconazole: Lessons Learnt from a Real-life Setting in a Tertiary Care Center in India. Indian J Crit Care Med 2023;27(6):451.
View Article and Find Full Text PDFIntroduction: Isavuconazole is an emerging therapeutic option for invasive infections caused by molds, especially aspergillosis and mucormycosis. Isavuconazole has predictable pharmacokinetics and good bioavailability. These attributes have led to some doubts regarding the need for therapeutic drug monitoring (TDM).
View Article and Find Full Text PDFObjectives: Posaconazole is a broad-spectrum triazole antifungal, with activity against various clinically important fungi. The delayed release (DR) tablet of posaconazole has been shown to have a superior pharmacokinetic profile in comparison with the oral suspension.
Methods: We retrospectively analyzed the factors associated with posaconazole levels <1.
Introduction: Invasive candidiasis is a serious infection seen in hospitalized or immunocompromised patients. Mortality rates for candidemia can be as high as 30-60%. is an emerging species of and is increasingly becoming a global public health problem.
View Article and Find Full Text PDFCoronavirus Disease (COVID-19) associated fungal infections including pulmonary aspergillosis, mucormycosis and other invasive fungal infections have been increasingly described in the current pandemic. osteomyelitis is a rare clinical form of aspergillosis. Most cases of osteomyelitis are reported in immunocompromised patients.
View Article and Find Full Text PDFBackground And Aim: India is facing the pandemic of coronavirus disease (COVID-19) just like the whole world. The private sector is the backbone of a healthcare facility in India. Presently, only a few major hospitals in the country are actively dealing with the COVID-19 patients while others are facing troubles due to lack of manpower, management, and required experience to face the pandemic.
View Article and Find Full Text PDF